Ipilimumab/nivolumab Reactions 1680, p190 - 2 Dec 2017 Autoimmune hypophysitis and hypoadrenocorticism: case report A 57-year-old woman developed autoimmune hypophysitis and hypoadrenocorticism following treatment with ipilimumab and nivolumab [routes not stated; not all time to reactions onsets stated]. The woman presented to the hospital with multiple metastatic melanoma lesions in the gastric wall, which were identified with endoscopy. She had a history of right uveal melanoma. At the first presentation, a CT scan demonstrated multiple metastatic lesions in the lungs and peritoneum. She was initiated on nivolumab 2 mg/kg per dose once every 3 weeks. However, another CT scan revealed progressive disease after six doses. Hence, four weeks after the last dose of nivolumab, she was initiated on ipilimumab 3 mg/kg per dose once every 3 weeks. She complained of fatigue, fever, muscle weakness and loss of appetite after two doses of nivolumab. Blood tests and head MRI revealed hypoadrenocorticism due to hypophysitis; assessed as treatment-related. The woman’s treatment with ipilimumab was discontinued and she received treatment with hydrocortisone. Subsequently, her symptoms improved. A month after the onset of hypoadrenocorticism, head MRI revealed no evidence of hypophysitis. Her hypoadrenocorticism was also successfully controlled by the hydrocortisone. Author comment: "At this point, blood tests and magnetic resonance imaging (MRI) of the head detected hypoadrenocorticism due to hypophysitis, which was assessed as being treatment-related." Ohnuma T, et al. Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis. Journal of Dermatology 44: 1325-1326, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1111/1346-8138.13692 - Japan 803285511 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial